Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Aileron Therapeutics Inc

Current price
5.35 USD +0.01 USD (+0.19%)
Last closed 5.93 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 29 361 916 USD
Yield for 12 month +230.25 %
21.11.2021 - 28.11.2021

Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts. Address: 285 Summer Street, Boston, MA, United States, 02210

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
MSFT MSFT Microsoft


WallStreet Target Price


P/E ratio

Dividend Yield

Current Year

Last Year

Current Quarter

Last Quarter

Current Year

Last Year

-169 000 USD

Current Quarter

-12 000 USD

Last Quarter

-12 000 USD

Key Figures ALRN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -12 639 000 USD
Operating Margin TTM
PE Ratio
Return On Assets TTM -39.79 %
PEG Ratio
Return On Equity TTM -76.36 %
Wall Street Target Price 9 USD
Revenue TTM
Book Value 2.47 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY
Dividend Yield
Gross Profit TTM -17 008 000 USD
Earnings Share -2.85 USD
Diluted Eps TTM -2.85 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics ALRN

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History ALRN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:20
Payout Ratio
Last Split Date 11.11.2022
Dividend Date

Stock Valuation ALRN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue
Price Sales TTM
Enterprise Value EBITDA -0.6953
Price Book MRQ 2.6788

Financials ALRN

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators ALRN

For 52 weeks

1.01 USD 7.12 USD
50 Day MA 5.31 USD
Shares Short Prior Month 32 951
200 Day MA 2.93 USD
Short Ratio 1.04
Shares Short 35 341
Short Percent 0.91 %

Dynamics of changes in the value of assets




414.58 USD Microsoft Corporation +0.12 (+0.03%)
Detailed analytics

ETF funds



208.70 CHF iShares MDAX UCITS ETF (DE) -11.84 (-4.92%)
Detailed analytics



2169.94 USD Gold -5.94 (-0.27%)
Detailed analytics